Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review

Detalhes bibliográficos
Autor(a) principal: Carvalho, Igor Nogueira Veloso
Data de Publicação: 2022
Outros Autores: Marambaia, Pablo Pinillos
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/29101
Resumo: Objective: To analyze the main treatment strategies for post-COVID-19 anosmia and hyposmia. Methods: Systematic review guided by PRISMA. The studies were searched between February and September 2021, in the electronic data sources of Pubmed, Cochrane (CENTRAL), LitCOVID and BVS. Inclusion criteria were clinical trials published from December 2019 to September 2021, on patients with maintenance of post-COVID-19 olfactory disorders, and the main existing treatment strategies were analyzed. Exclusion criteria were studies published before December 2019, performed in patients under 18 years of age and other types of study designs. Risk of bias analysis was performed using the ROB 2.0 tool for randomized clinical trials, and ROBINS-I for non-randomized trials. Results: Five articles were selected. A total of 237 patients with maintenance of post-COVID-19 olfactory disorders were evaluated. The follow-up of the patients' olfactory function ranged from a minimum of 3 weeks to a maximum of 10 weeks. The treatment modalities that demonstrated the greatest benefits to the olfactory function of these patients were corticosteroids and olfactory training. Conclusion: Treatment for post-COVID-19 anosmia and hyposmia should be started two weeks after the onset of olfactory symptoms. The use of corticosteroids and the practice of olfactory training are the treatment modalities that presented the best evidence regarding the recovery of olfactory function. Other less conventional modalities lack more robust evidence and cannot yet be recommended.
id UNIFEI_5bbbce6a88f7f0ab0c7f797398874d69
oai_identifier_str oai:ojs.pkp.sfu.ca:article/29101
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic reviewModalidades de tratamiento para la anosmia e hiposmia post-COVID-19: una revisión sistemática Modalidades de tratamento para anosmia e hiposmia pós-COVID-19: uma revisão sistemáticaCOVID-19SARS-COV-2AnosmiaHiposmiaTratamento.COVID-19SARS-COV-2AnosmiaHyposmiaTreatment.COVID-19SARS-COV-2AnosmiaHiposmiaTratamiento.Objective: To analyze the main treatment strategies for post-COVID-19 anosmia and hyposmia. Methods: Systematic review guided by PRISMA. The studies were searched between February and September 2021, in the electronic data sources of Pubmed, Cochrane (CENTRAL), LitCOVID and BVS. Inclusion criteria were clinical trials published from December 2019 to September 2021, on patients with maintenance of post-COVID-19 olfactory disorders, and the main existing treatment strategies were analyzed. Exclusion criteria were studies published before December 2019, performed in patients under 18 years of age and other types of study designs. Risk of bias analysis was performed using the ROB 2.0 tool for randomized clinical trials, and ROBINS-I for non-randomized trials. Results: Five articles were selected. A total of 237 patients with maintenance of post-COVID-19 olfactory disorders were evaluated. The follow-up of the patients' olfactory function ranged from a minimum of 3 weeks to a maximum of 10 weeks. The treatment modalities that demonstrated the greatest benefits to the olfactory function of these patients were corticosteroids and olfactory training. Conclusion: Treatment for post-COVID-19 anosmia and hyposmia should be started two weeks after the onset of olfactory symptoms. The use of corticosteroids and the practice of olfactory training are the treatment modalities that presented the best evidence regarding the recovery of olfactory function. Other less conventional modalities lack more robust evidence and cannot yet be recommended.Objetivo: Analizar las principales estrategias de tratamiento de la anosmia e hiposmia post-COVID-19. Métodos: Revisión sistemática guiada por PRISMA. Los articulos fueron buscados entre febrero y septiembre de 2021, en las fuentes de datos electrónicos de Pubmed, Cochrane (CENTRAL), LitCOVID y BVS. Los criterios de inclusión fueron ensayos clínicos publicados desde diciembre de 2019 hasta septiembre de 2021, en pacientes con persistencia de trastornos del olfato post-COVID-19, y se analizaron las principales estrategias de tratamiento existentes. Los criterios de exclusión fueron estudios publicados antes de diciembre de 2019, realizados en pacientes menores de 18 años y otros tipos de diseños. El análisis del riesgo de sesgo se realizó con la herramienta ROB 2.0 para ensayos clínicos aleatorizados y ROBINS-I para ensayos no aleatorizados. Resultados: Se seleccionaron cinco artículos. Se evaluaron un total de 237 pacientes con persistencia de trastornos olfativos post-COVID-19. El seguimiento de la función olfativa de los pacientes osciló entre un mínimo de 3 semanas y un máximo de 10 semanas. Las modalidades de tratamiento que demostraron mayores beneficios para la función olfativa de estos pacientes fueron los corticoides y el entrenamiento olfativo. Conclusión: El tratamiento de la anosmia e hiposmia post-COVID-19 debe iniciarse dos semanas después del inicio de los síntomas olfativos. El uso de corticoides y la práctica del entrenamiento olfativo son las modalidades de tratamiento que presentaron mejor evidencia en cuanto a la recuperación de la función olfativa. Otras modalidades menos convencionales carecen de evidencia más sólida y aún no pueden recomendarse.Objetivo: Analisar as principais estratégias de tratamento para anosmia e hiposmia pós-COVID-19. Métodos: Revisão Sistemática norteada pelo PRISMA. Os estudos foram buscados entre fevereiro e setembro de 2021, nas fontes de dados eletrônicas do Pubmed, Cochrane (CENTRAL), LitCOVID e BVS. Os critérios de inclusão foram e nsaios clínicos publicados de dezembro de 2019 até setembro de 2021, sobre pacientes com manutenção dos distúrbios olfatórios pós-COVID-19, e as principais estratégias de tratamento existentes foram analisadas. Os critérios de exclusão foram estudos publicados antes de dezembro de 2019, realizados em pacientes menores de 18 anos e outros tipos de delineamentos. A análise do risco de viés foi realizada através da ferramenta ROB 2.0 para os ensaios clínicos randomizados, e a ROBINS-I para os não randomizados. Resultados: Cinco artigos foram selecionados. Um total de 237 pacientes com manutenção dos distúrbios olfatórios pós-COVID-19 foi avaliado. O acompanhamento da função olfatória dos pacientes variou de no mínimo 03 semanas e no máximo 10 semanas. As modalidades de tratamento que demonstraram maiores benefícios à função olfatória desses pacientes foram os corticosteroides e o treinamento olfatório. Conclusão: O tratamento para anosmia e hiposmia pós-COVID-19 deve ser iniciado após duas semanas do início dos sintomas olfativos. O uso de corticosteroides e a prática do treinamento olfatório são as modalidades de tratamento que apresentaram as melhores evidências em relação à recuperação da função olfatória. Outras modalidades menos convencionais carecem de evidências mais robustas e ainda não podem ser recomendadas.Research, Society and Development2022-04-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2910110.33448/rsd-v11i6.29101Research, Society and Development; Vol. 11 No. 6; e36911629101Research, Society and Development; Vol. 11 Núm. 6; e36911629101Research, Society and Development; v. 11 n. 6; e369116291012525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/29101/25299Copyright (c) 2022 Igor Nogueira Veloso Carvalho; Pablo Pinillos Marambaiahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccess Carvalho, Igor Nogueira VelosoMarambaia, Pablo Pinillos 2022-05-13T18:04:10Zoai:ojs.pkp.sfu.ca:article/29101Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:46:16.466097Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
Modalidades de tratamiento para la anosmia e hiposmia post-COVID-19: una revisión sistemática
Modalidades de tratamento para anosmia e hiposmia pós-COVID-19: uma revisão sistemática
title Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
spellingShingle Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
Carvalho, Igor Nogueira Veloso
COVID-19
SARS-COV-2
Anosmia
Hiposmia
Tratamento.
COVID-19
SARS-COV-2
Anosmia
Hyposmia
Treatment.
COVID-19
SARS-COV-2
Anosmia
Hiposmia
Tratamiento.
title_short Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
title_full Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
title_fullStr Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
title_full_unstemmed Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
title_sort Treatment modalities for post-COVID-19 anosmia and hyposmia: a systematic review
author Carvalho, Igor Nogueira Veloso
author_facet Carvalho, Igor Nogueira Veloso
Marambaia, Pablo Pinillos
author_role author
author2 Marambaia, Pablo Pinillos
author2_role author
dc.contributor.author.fl_str_mv Carvalho, Igor Nogueira Veloso
Marambaia, Pablo Pinillos
dc.subject.por.fl_str_mv COVID-19
SARS-COV-2
Anosmia
Hiposmia
Tratamento.
COVID-19
SARS-COV-2
Anosmia
Hyposmia
Treatment.
COVID-19
SARS-COV-2
Anosmia
Hiposmia
Tratamiento.
topic COVID-19
SARS-COV-2
Anosmia
Hiposmia
Tratamento.
COVID-19
SARS-COV-2
Anosmia
Hyposmia
Treatment.
COVID-19
SARS-COV-2
Anosmia
Hiposmia
Tratamiento.
description Objective: To analyze the main treatment strategies for post-COVID-19 anosmia and hyposmia. Methods: Systematic review guided by PRISMA. The studies were searched between February and September 2021, in the electronic data sources of Pubmed, Cochrane (CENTRAL), LitCOVID and BVS. Inclusion criteria were clinical trials published from December 2019 to September 2021, on patients with maintenance of post-COVID-19 olfactory disorders, and the main existing treatment strategies were analyzed. Exclusion criteria were studies published before December 2019, performed in patients under 18 years of age and other types of study designs. Risk of bias analysis was performed using the ROB 2.0 tool for randomized clinical trials, and ROBINS-I for non-randomized trials. Results: Five articles were selected. A total of 237 patients with maintenance of post-COVID-19 olfactory disorders were evaluated. The follow-up of the patients' olfactory function ranged from a minimum of 3 weeks to a maximum of 10 weeks. The treatment modalities that demonstrated the greatest benefits to the olfactory function of these patients were corticosteroids and olfactory training. Conclusion: Treatment for post-COVID-19 anosmia and hyposmia should be started two weeks after the onset of olfactory symptoms. The use of corticosteroids and the practice of olfactory training are the treatment modalities that presented the best evidence regarding the recovery of olfactory function. Other less conventional modalities lack more robust evidence and cannot yet be recommended.
publishDate 2022
dc.date.none.fl_str_mv 2022-04-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/29101
10.33448/rsd-v11i6.29101
url https://rsdjournal.org/index.php/rsd/article/view/29101
identifier_str_mv 10.33448/rsd-v11i6.29101
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/29101/25299
dc.rights.driver.fl_str_mv Copyright (c) 2022 Igor Nogueira Veloso Carvalho; Pablo Pinillos Marambaia
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Igor Nogueira Veloso Carvalho; Pablo Pinillos Marambaia
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 6; e36911629101
Research, Society and Development; Vol. 11 Núm. 6; e36911629101
Research, Society and Development; v. 11 n. 6; e36911629101
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052811814371328

Registros relacionados